PortfoliosLab logoPortfoliosLab logo
ABCL vs. NTLA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ABCL vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AbCellera Biologics Inc. (ABCL) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ABCL achieves a 64.62% return, which is significantly lower than NTLA's 69.63% return.


ABCL

1D
-1.92%
1M
8.27%
YTD
64.62%
6M
52.57%
1Y
69.07%
3Y*
-8.34%
5Y*
-23.34%
10Y*

NTLA

1D
-3.17%
1M
21.03%
YTD
69.63%
6M
61.89%
1Y
65.22%
3Y*
-28.07%
5Y*
-29.38%
10Y*
-5.26%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ABCL vs. NTLA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ABCL
AbCellera Biologics Inc.
64.62%16.72%-48.69%-43.63%-29.16%-64.46%-34.03%
NTLA
Intellia Therapeutics, Inc.
69.63%-22.90%-61.76%-12.61%-70.49%117.35%-2.61%

Correlation

The correlation between ABCL and NTLA is 0.54, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.54

Correlation (3Y)
Calculated over the trailing 3-year period

0.59

Correlation (5Y)
Calculated over the trailing 5-year period

0.54

Correlation (All Time)
Calculated using the full available price history since Dec 11, 2020

0.51

The correlation between ABCL and NTLA has been stable across timeframes, ranging from 0.51 to 0.59 - a consistent structural relationship.

Fundamentals

Market Cap

ABCL:

$1.71B

NTLA:

$1.81B

EPS

ABCL:

-$0.48

NTLA:

-$3.58

PS Ratio

ABCL:

21.31

NTLA:

25.43

PB Ratio

ABCL:

1.82

NTLA:

2.91

Total Revenue (TTM)

ABCL:

$79.21M

NTLA:

$66.09M

Gross Profit (TTM)

ABCL:

$70.89M

NTLA:

-$33.92M

EBITDA (TTM)

ABCL:

-$166.07M

NTLA:

-$299.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ABCL vs. NTLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABCL
ABCL Risk / Return Rank: 6868
Overall Rank
ABCL Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
ABCL Sortino Ratio Rank: 7171
Sortino Ratio Rank
ABCL Omega Ratio Rank: 6767
Omega Ratio Rank
ABCL Calmar Ratio Rank: 6767
Calmar Ratio Rank
ABCL Martin Ratio Rank: 6464
Martin Ratio Rank

NTLA
NTLA Risk / Return Rank: 6464
Overall Rank
NTLA Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 6767
Sortino Ratio Rank
NTLA Omega Ratio Rank: 6969
Omega Ratio Rank
NTLA Calmar Ratio Rank: 6262
Calmar Ratio Rank
NTLA Martin Ratio Rank: 5858
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABCL vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ABCLNTLADifference
Sharpe ratioReturn per unit of total volatility

+0.23

Sortino ratioReturn per unit of downside risk

+0.21

Omega ratioGain probability vs. loss probability

1.19

1.21

-0.02

Calmar ratioReturn relative to maximum drawdown

1.26

0.92

+0.34

Martin ratioReturn relative to average drawdown

2.29

1.41

+0.88

ABCL vs. NTLA - Sharpe Ratio Comparison

The current ABCL Sharpe Ratio is 0.89, which is higher than the NTLA Sharpe Ratio of 0.66. The chart below compares the historical Sharpe Ratios of ABCL and NTLA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ABCL vs. NTLA - Drawdown Comparison

The maximum ABCL drawdown since its inception was -96.84%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for ABCL and NTLA.


Loading charts...

Drawdown Indicators


ABCLNTLADifference

Max Drawdown

Largest peak-to-trough decline

-96.84%

-96.45%

-0.39%

Max Drawdown (1Y)

Largest decline over 1 year

-54.94%

-71.27%

+16.33%

Max Drawdown (3Y)

Largest decline over 3 years

-75.72%

-86.28%

+10.56%

Max Drawdown (5Y)

Largest decline over 5 years

-91.23%

-96.45%

+5.22%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

-90.77%

-91.37%

+0.60%

Average Drawdown

Average peak-to-trough decline

-84.16%

-57.19%

-26.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.23%

46.34%

-16.11%

Volatility

ABCL vs. NTLA - Volatility Comparison

The current volatility for AbCellera Biologics Inc. (ABCL) is 24.71%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 29.47%. This indicates that ABCL experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ABCLNTLADifference

Volatility (1M)

Calculated over the trailing 1-month period

24.71%

29.47%

-4.76%

Volatility (6M)

Calculated over the trailing 6-month period

55.13%

58.34%

-3.21%

Volatility (1Y)

Calculated over the trailing 1-year period

77.80%

98.89%

-21.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.88%

81.41%

-14.53%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

70.24%

78.80%

-8.56%

Dividends

ABCL vs. NTLA - Dividend Comparison

Neither ABCL nor NTLA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ABCL vs. NTLA - Financials Comparison

This section allows you to compare key financial metrics between AbCellera Biologics Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M20222023202420252026
8.32M
15.05M
(ABCL) Total Revenue
(NTLA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ABCL and NTLA have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NTLA has higher volatility (29.47%) compared to ABCL (24.71%). In terms of maximum drawdown, ABCL dropped -96.84% vs NTLA's -96.45%.

ABCL currently has the higher Sharpe Ratio (0.89 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ABCL and NTLA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer